Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline Review, H2 2019

December 2019 | 255 pages | ID: C7BAAB74448EN
Global Markets Direct

Abstracts

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline Review, H2 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Clostridium difficile Infections - Pipeline Review, H2 2019, provides an overview of the Clostridium difficile Infections (Infectious Disease) pipeline landscape.

Clostridium difficile infections are caused by Clostridium difficile, often called C. difficile or C. diff, a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Symptoms of C. diff infection includes watery diarrhea, with abdominal pain or tenderness, loss of appetite, fever, blood or pus in the stool and weight loss. Risk factors are age, surgery of the gastrointestinal (GI) tract, a weakened immune system, kidney disease, use of drugs called proton-pump inhibitors, which lessen stomach acid and use of chemotherapy drugs. This condition may be controlled by the use of medication such as antibiotics and may be prevented by lifestyle modification.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Clostridium difficile Infections - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Clostridium difficile Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Clostridium difficile Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Clostridium difficile Infections (Clostridium difficile Associated Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 4, 10, 11, 39, 17 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 7 molecules, respectively.

Clostridium difficile Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Clostridium difficile Infections (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Clostridium difficile Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Clostridium difficile Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Clostridium difficile Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Clostridium difficile Infections (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Clostridium difficile Infections (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Clostridium difficile Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Overview
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Therapeutics Development
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Therapeutics Assessment
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Companies Involved in Therapeutics Development
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Drug Profiles
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Discontinued Products
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects, H2 2019
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects, H2 2019 (Contd..1), H2 2019
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects, H2 2019 (Contd..2), H2 2019
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects, H2 2019 (Contd..3), H2 2019
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019

COMPANIES MENTIONED

Absynth Biologics Ltd
Acurx Pharmaceuticals LLC
Akthelia Pharmaceuticals Ltd
Appili Therapeutics Inc
Aviex Technologies LLC
AzurRx BioPharma Inc
Biomica
Botanix Pharmaceuticals Ltd
Boulos and Cooper Pharmaceuticals Pty Ltd
Chain Biotechnology Ltd
Crestone Inc
CSA Biotechnologies LLC
Daiichi Sankyo Co Ltd
Deinove SAS
Enterobiotix Ltd
Facile Therapeutics Inc
Ferring International Center SA
Finch Therapeutics Group
Fzata Inc
GlaxoSmithKline Plc
Immune Biosolutions Inc
ImmuneBiotech AB
ImmuniMed Inc
ImmunoBiology Ltd
Immuron Ltd
Inositec AG
Inovio Pharmaceuticals Inc
Inspyr Therapeutics Inc
Integrated BioTherapeutics Inc
Kaleido Biosciences Inc
KamTek Inc
KoBioLabs Inc
Locus Biosciences Inc
Mapp Biopharmaceutical Inc
Matrivax Research & Development Corp
Merck & Co Inc
MGB Biopharma Ltd
Microbiotica Ltd
Micropharm Ltd
Miyarisan Pharmaceutical Company Ltd
MyBiotics Pharma Ltd
Novabiotics Ltd
NovoBiotic Pharmaceuticals LLC
Nubiyota LLC
Oragenics Inc
Otsuka Holdings Co Ltd
PanTheryx Inc
Pfizer Inc
Procarta Biosystems Ltd
Proxi Biotech IVS
Pylum Biosciences Inc
Q2 Pharma Ltd
QureTech Bio AB
Recursion Pharmaceuticals Inc
Rise Therapeutics LLC
SciBac Inc
Scioto Biosciences Inc
Seres Therapeutics Inc
Serometrix LLC
Servatus Ltd
Summit Therapeutics Plc
Symbiotic Health Inc
Synthetic Biologics Inc
Valevia UK Ltd
Valneva SE
Vedanta Biosciences Inc
Vitality Biopharma Inc
XBiotech Inc